Report of a workshop on malignant lymphoma: A review of molecular and clinical risk profiling

British Journal of Haematology

Volumn 142, Issue 2, 2008, Pages 166-178

  Gleissner, B ^a   Kuppers R ^b   Siebert, R ^c   Glass, B ^d   Trumper L ^d   Hiddemann, W ^e   Dreyling, M ^e  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antibody therapy; Lymphomas; Prognostic factors

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AG 024322; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CALICHEAMICIN DERIVATIVE; CMC 544; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; FLAVOPIRIDOL; GALIXIMAB; INTERLEUKIN 13; LENALIDOMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HCD 122; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; ROSCOVITINE; SGN 40; TEMSIROLIMUS; VINCRISTINE; VORINOSTAT;

B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DISEASE COURSE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; SURVIVAL RATE; T LYMPHOCYTE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; CELL CYCLE; HUMANS; LYMPHOMA; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; PROGNOSIS; RISK FACTORS;

EID: 47349105801     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07138.x     Document Type: Review

References (93)

1. Advani, R.H., Furman, R.R., Rosenblatt, J.D., Younes, A., Forero-Torres, A., Harrop, K.L., Baumgartner, K.T., McDonald, M. Drachman, J.G. (2005) A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma. Blood, 106, 433A.
2. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.G., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L.M., Marti, G.E., Moore, T., Hudson, J., Lu, L.S., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503 511.
3. Alvaro, T., Lejeune, M., Camacho, F.I., Salvado, M.T., Sanchez, L., Garcia, J.F., Lopez, C., Jaen, J., Bosch, R., Pons, L.E., Bellas, C. Piris, M.A. (2006) The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica, 91, 1605 1612.
4. Bea, S., Zettl, A., Wright, G., Salaverria, I., Jehn, P., Moreno, V., Burek, C., Ott, G., Puig, X., Yang, L., Lopez-Guillermo, A., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Gascoyne, R.D., Connors, J.M., Grogan, T.M., Braziel, R., Fisher, R.I., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Simon, R., Powell, J., Wilson, W.H., Jaffe, E.S., Montserrat, E., Muller-Hermelink, H.K., Staudt, L.M., Campo, E. Rosenwald, A. (2005) Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood, 106, 3183 3190.
5. Belch, A., Kouroukis, C.T., Crump, M., Sehn, L., Gascoyne, R.D., Klasa, R., Powers, J., Wright, J. Eisenhauer, E.A. (2007) A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Annals of Oncology, 18, 116 121.
6. Bilalovic, N., Blystad, A.K., Golouh, R., Nesland, J.M., Selak, I., Trinh, D. Torlakovic, E. (2004) Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. American Journal of Clinical Pathology, 121, 34 42.
7. Bosga-Bouwer, A.G., van den, B.A., Haralambieva, E., De Jong, D., Boonstra, R., Kluin, P., van den, B.E. Poppema, S. (2006) Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Human Pathology, 37, 528 533.
8. Bruggemann, M., Raff, T., Flohr, T., Gokbuget, N., Nakao, M., Droese, J., Luschen, S., Pott, C., Ritgen, M., Scheuring, U., Horst, H.A., Thiel, E., Hoelzer, D., Bartram, C.R. Kneba, M. (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood, 107, 1116 1123.
9. Buchonnet, G., Jardin, F., Jean, N., Bertrand, P., Parmentier, F., Tison, S., Lepretre, S., Contentin, N., Lenain, P., Stamatoullas-Bastard, A., Tilly, H. Bastard, C. (2002) Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease? Leukemia, 16, 1852 1856.
10. Buske, C., Hoster, E., Dreyling, M., Hasford, J., Unterhalt, M. Hiddemann, W. (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood, 108, 1504 1508.
11. Byrd, J.C., Flinn, I.W., Khan, K.D., Kipps, T.J., Aukerman, L., Fox, J., Girish, S., Guzy, S., Bilic, S., Solinger, A., Dort, S., Wang, Y.Y., Hurst, D. O'Brien, S. (2006) Pharmaco kinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12), in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 108, 803A.
12. Canioni, D., Salles, G., Mounier, N., Brousse, N., Keuppens, M., Morchauser, F., Fournier, M., Lamy, T., Rousselet, M.C., Foussard, C. Xerri, L. (2006) The poor prognosis value of high intra-tumoral macrophages counts in follicular lymphoma patients requires selection of appropriate cut-off and can be circumvented by rituximab therapy. Blood, 108, 822a.
13. Carreras, J., Lopez-Guillermo, A., Fox, B.C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E. Banham, A.H. (2006) High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 108, 2957 2964.
14. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754 758.
15. Corradini, P., Ladetto, M., Zallio, F., Astolfi, M., Rizzo, E., Sametti, S., Cuttica, A., Rosato, R., Farina, L., Boccadoro, M., Benedetti, F., Pileri, A. Tarella, C. (2004) Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. Journal of Clinical Oncology, 22, 1460 1468.
16. Dave, S.S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R.D., Chan, W.C., Fisher, R.I., Braziel, R.M., Rimsza, L.M., Grogan, T.M., Miller, T.P., Leblanc, M., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Connors, J.M., Lansdorp, P.M., Ouyang, Q., Lister, T.A., Davies, A.J., Norton, A.J., Muller-Hermelink, H.K., Ott, G., Campo, E., Montserrat, E., Wilson, W.H., Jaffe, E.S., Simon, R., Yang, L., Powell, J., Zhao, H., Goldschmidt, N., Chiorazzi, M. Staudt, L.M. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. The New England Journal of Medicine, 351, 2159 2169.
17. Dave, S.S., Fu, K., Wright, G.W., Lam, L.T., Kluin, P., Boerma, E.J., Greiner, T.C., Weisenburger, D.D., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Delabie, J., Rimsza, L.M., Braziel, R.M., Grogan, T.M., Campo, E., Jaffe, E.S., Dave, B.J., Sanger, W., Bast, M., Vose, J.M., Armitage, J.O., Connors, J.M., Smeland, E.B., Kvaloy, S., Holte, H., Fisher, R.I., Miller, T.P., Montserrat, E., Wilson, W.H., Bahl, M., Zhao, H., Yang, L., Powell, J., Simon, R., Chan, W.C. Staudt, L.M. (2006) Molecular diagnosis of Burkitt's lymphoma. The New England Journal of Medicine, 354, 2431 2442.
18. De Jong, D. (2005) Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. Journal of Clinical Oncology, 23, 6358 6363.
19. De Jong, D., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Lee, A., Sander, B., Thorns, C., Campo, E., Molina, T., Norton, A., Hagenbeek, A., Horning, S., Lister, A., Raemaekers, J., Gascoyne, R.D., Salles, G. Weller, E. (2007) Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology, 25, 805 812.
20. Dreyling, M., Lenz, G., Hoster, E., Van, H.A., Gisselbrecht, C., Schmits, R., Metzner, B., Truemper, L., Reiser, M., Steinhauer, H., Boiron, J.M., Boogaerts, M.A., Aldaoud, A., Silingardi, V., Kluin-Nelemans, H.C., Hasford, J., Parwaresch, R., Unterhalt, M. Hiddemann, W. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood, 105, 2677 2684.
21. Dunleavy, K., Pittaluga, S., Janik, J., Grant, N., Steinberg, S., Staudt, L., Jaffe, E. Wilson, W.H. (2005) Primary mediastinal large B-cell lymphoma (PMBL) outcome is significantly improved by the addition of rituximab to dose adjusted (DA)-EPOCH and overcomes the need for radiation. Blood, 106, 273A.
22. Elpek, K.G., Lacelle, C., Singh, N.P., Yolcu, E.S. Shirwan, H. (2007) CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. Journal of Immunology, 178, 6840 6848.
23. Engelhard, M., Brittinger, G., Huhn, D., Gerhartz, H.H., Meusers, P., Siegert, W., Thiel, E., Wilmanns, W., Aydemir, U., Bierwolf, S., Griesser, H., Tiemann, M. Lennert, K. (1997) Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood, 89, 2291 2297.
24. Farinha, P., Masoudi, H., Skinnider, B.F., Shumansky, K., Spinelli, J.J., Gill, K., Klasa, R., Voss, N., Connors, J.M. Gascoyne, R.D. (2005) Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 106, 2169 2174.
25. Fayad, L., Patel, H., Verhoef, G., Czuczman, M., Foran, J., Gine, E., Rohatiner, A., Smith, M.R., Shapiro, M. Advani, A. (2006) Clinical activity of the immunoconjugate CMC-544 in B-Cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study. Blood, 108, 766A.
26. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de, V.S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867 4874.
27. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Bock, H.P., Wandt, H., Unterhalt, M. Hiddemann, W. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, 3064 3071.
28. Freedman, A.S., Neuberg, D., Mauch, P., Soiffer, R.J., Anderson, K.C., Fisher, D.C., Schlossman, R., Alyea, E.P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L.M. Gribben, J.G. (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood, 94, 3325 3333.
29. Fu, K., Weisenburger, D.D., Greiner, T.C., Dave, S., Wright, G., Rosenwald, A., Chiorazzi, M., Iqbal, J., Gesk, S., Siebert, R., De Jong, D., Jaffe, E.S., Wilson, W.H., Delabie, J., Ott, G., Dave, B.J., Sanger, W.G., Smith, L.M., Rimsza, L., Braziel, R.M., Muller-Hermelink, H.K., Campo, E., Gascoyne, R.D., Staudt, L.M. Chan, W.C. (2005) Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood, 106, 4315 4321.
30. Gesk, S., Klapper, W., Martin-Subero, J.I., Nagel, I., Harder, L., Fu, K., Bernd, H.W., Weisenburger, D.D., Parwaresch, R. Siebert, R. (2006) A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood, 108, 1109 1110.
31. Glas, A.M., Kersten, M.J., Delahaye, L.J., Witteveen, A.T., Kibbelaar, R.E., Velds, A., Wessels, L.F., Joosten, P., Kerkhoven, R.M., Bernards, R., van Krieken, J.H., Kluin, P.M., van't Veer, L.J. De Jong, D. (2005) Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood, 105, 301 307.
32. Glas, A.M., Knoops, L., Delahaye, L., Kersten, M.J., Kibbelaar, R.E., Wessels, L.A., van, L.R., van Krieken, J.H., Baars, J.W., Raemaekers, J., Kluin, P.M., van't Veer, L.J. De Jong, D. (2007) Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. Journal of Clinical Oncology, 25, 390 398.
33. Glass, B., Kloess, M., Engert, A., Berdel, W., Metzner, B., Tromper, L., Loeffler, M., Pfreundschuh, M. Schmitz, N. (2005) Dose escalated CHOP plus etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL. Journal of Clinical Oncology, 23, 598S.
34. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275 282.
35. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. Bloomfield, C.D. (2000) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Modern Pathology, 13, 193 207.
36. Heider, U., von, M.I., Kaiser, M., Rosche, M., Sterz, J., Rotzer, S., Rademacher, J., Jakob, C., Fleissner, C., Kuckelkorn, U., Kloetzel, P.M. Sezer, O. (2008) Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. European Journal of Haematology, 80, 133 142.
37. Hernandez, L., Bea, S., Pinyol, M., Ott, G., Katzenberger, T., Rosenwald, A., Bosch, F., Lopez-Guillermo, A., Delabie, J., Colomer, D., Montserrat, E. Campo, E. (2005) CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Research, 65, 2199 2206.
38. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725 3732.
39. Hoglund, M., Sehn, L., Connors, J.M., Gascoyne, R.D., Siebert, R., Sall, T., Mitelman, F. Horsman, D.E. (2004) Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes, Chromosomes and Cancer, 39, 195 204.
40. Hoster, E., Dreyling, M., Unterhalt, M., Hasford, J. Hiddemann, W. (2007) A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 108, 814a. Ref Type: Generic.
41. Hummel, M., Bentink, S., Berger, H., Klapper, W., Wessendorf, S., Barth, T.F.E., Bernd, H.W., Cogliatti, S.B., Dierlamm, J., Feller, A.C., Hansmann, M.L., Haralambieva, E., Harder, L., Hasenclever, D., Kuhn, M., Lenze, D., Lichter, P., Martin-Subero, J.I., Moller, P., Muller-Hermelink, H.K., Ott, G., Parwaresch, R.M., Pott, C., Rosenwald, A., Rosolowski, M., Schwaenen, C., Sturzenhofecker, B., Szczepanowski, M., Trautmann, H., Wacker, H.H., Spang, R., Loeffler, M., Trumper, L., Stein, H. Siebert, R. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. New England Journal of Medicine, 354, 2419 2430.
42. Iqbal, J., Neppalli, V.T., Wright, G., Dave, B.J., Horsman, D.E., Rosenwald, A., Lynch, J., Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Campo, E., Ott, G., Muller-Hermelink, H.K., Delabie, J., Jaffe, E.S., Grogan, T.M., Connors, J.M., Vose, J.M., Armitage, J.O., Staudt, L.M. Chan, W.C. (2006) BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 961 968.
43. Jardin, F., Gaulard, P., Buchonnet, G., Contentin, N., Lepretre, S., Lenain, P., Stamatoullas, A., Picquenot, J.M., Duval, C., Parmentier, F., Tilly, H. Bastard, C. (2002) Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics. Leukemia, 16, 2309 2317.
44. Johansson, B., Mertens, F. Mitelman, F. (1995) Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood, 86, 3905 3914.
45. Katzenberger, T., Ott, G., Klein, T., Kalla, J., Muller-Hermelink, H.K. Ott, M.M. (2004) Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. The American Journal of Pathology, 165, 481 490.
46. Katzenberger, T., Petzoldt, C., Holler, S., Mader, U., Kalla, J., Adam, P., Ott, M.M., Muller-Hermelink, H.K., Rosenwald, A. Ott, G. (2006) The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood, 107, 3407.
47. Kawamata, N., Chen, J. Koeffler, H.P. (2007) Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood, 110, 2667 2673.
48. Kelley, S.K., Gelzleichter, T., Xie, D., Lee, W.P., Darbonne, W.C., Qureshi, F., Kissler, K., Oflazoglu, E. Grewal, I.S. (2006) Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. British Journal of Pharmacology, 148, 1116 1123.
49. Klapper, W., Hoster, E., Rolver, L., Schrader, C., Janssen, D., Tiemann, M., Bernd, H.W., Determann, O., Hansmann, M.L., Moller, P., Feller, A., Stein, H., Wacker, H.H., Dreyling, M., Unterhalt, M., Hiddemann, W. Ott, G. (2007) Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. Journal of Clinical Oncology, 25, 3330 3336.
50. Kneba, M., Bolz, I., Linke, B. Hiddemann, W. (1995) Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. Blood, 86, 3930 3937.
51. Kube, D., Hua, T.D., Kloss, M., Kulle, B., Brockmoller, J., Wojnowski, L., Loffler, M., Pfreundschuh, M. Trumper, L. (2007) The interleukin-10 gene promoter polymorphism - 1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes and Immunity, 8, 164 167.
52. Lam, L.T., Wright, G., Davis, R.E., Lenz, G., Farinha, P., Dang, L., Chan, J.W., Rosenwald, A., Gascoyne, R.D. Staudt, L.M. (2008) Cooperative signaling through the STAT3 and NF-{kappa}B pathways in subtypes of diffuse large B cell lymphoma. Blood, January, doi:.
53. Lee, A.M., Clear, A.J., Calaminici, M., Davies, A.J., Jordan, S., Macdougall, F., Matthews, J., Norton, A.J., Gribben, J.G., Lister, T.A. Goff, L.K. (2006) Number of CD4+ Cells and location of Forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. Journal of Clinical Oncology, 24, 5052 5059.
54. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt, M. Hiddemann, W. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Journal of Clinical Oncology, 23, 1984 1992.
55. Leonard, J.P., Friedberg, J.W., Younes, A., Fisher, D., Gordon, L.I., Moore, J., Czuczman, M., Miller, T., Stiff, P., Cheson, B.D., Forero-Torres, A., Chieffo, N., McKinney, B., Finucane, D. Molina, A. (2007) A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Annals of Oncology, 18, 1216 1223.
56. Lossos, I.S., Czerwinski, D.K., Alizadeh, A.A., Wechser, M.A., Tibshirani, R., Botstein, D. Levy, R. (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. The New England Journal of Medicine, 350, 1828 1837.
57. Masir, N., Marafioti, T., Jones, M., Natkunam, Y., Rudiger, T., Hansmann, M.L. Mason, D.Y. (2006) Loss of CD19 expression in B-cell neoplasms. Histopathology, 48, 239 246.
58. Micallef, I.N., Kahl, B.S., Maurer, M.J., Dogan, A., Ansell, S.M., Colgan, J.P., Geyer, S., Inwards, D.J., White, W.L. Habermann, T.M. (2006) A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer, 107, 2826 2832.
59. Mounier, N., Briere, J., Gisselbrecht, C., Emile, J.F., Lederlin, P., Sebban, C., Berger, F., Bosly, A., Morel, P., Tilly, H., Bouabdallah, R., Reyes, F., Gaulard, P. Coiffier, B. (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood, 101, 4279 4284.
60. Nyman, H., Adde, M., Karjalainen-Lindsberg, M.L., Taskinen, M., Berglund, M., Amini, R.M., Blomqvist, C., Enblad, G. Leppa, S. (2007) Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood, 109, 4930 4935.
61. Ott, G., Katzenberger, T., Lohr, A., Kindelberger, S., Rudiger, T., Wilhelm, M., Kalla, J., Rosenwald, A., Muller, J.G., Ott, M.M. Muller-Hermelink, H.K. (2002) Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood, 99, 3806 3812.
62. Perez-Galan, P., Roue, G., Villamor, N., Campo, E. Colomer, D. (2007) The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood, 109, 4441 4449.
63. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology, 7, 379 391.
64. Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trumper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C. Loeffler, M. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology, 9, 105 116.
65. Pott, C., Schrader, C., Gesk, S., Harder, L., Tiemann, M., Raff, T., Bruggemann, M., Ritgen, M., Unterhalt, M., Dreyling, M., Hiddemann, W., Siebert, R., Dreger, P. Kneba, M. (2005) Quantitative assessment of molecular remission following autologous stem cell transplantation predicts long term remission in mantle cell lymphoma. Blood, 106, 916A.
66. Pozzobon, M., Marafioti, T., Hansmann, M.L., Natkunam, Y. Mason, D.Y. (2004) Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples. British Journal of Haematology, 124, 519 533.
67. Qu, Z., Goldenberg, D.M., Cardillo, T.M., Shi, V., Hansen, H.J. Chang, C.H. (2008) Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood, 111, 2211 2219.
68. Rambaldi, A., Carlotti, E., Oldani, E., la Starza, I., Baccarani, M., Cortelazzo, S., Lauria, F., Arcaini, L., Morra, E., Pulsoni, A., Rigacci, L., Rupolo, M., Zaja, F., Zinzani, P.L., Barbui, T. Foa, R. (2005) Quantitative PCR of bone marrow BCL2/IgH(+) cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood, 105, 3428 3433.
69. Renne, C., Willenbrock, K., Martin-Subero, J.I., Hinsch, N., Doring, C., Tiacci, E., Klapper, W., Moller, P., Kuppers, R., Hansmann, M.L., Siebert, R. Brauninger, A. (2007) High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia, 21, 780 787.
70. Rimokh, R., Berger, F., Delsol, G., Charrin, C., Bertheas, M.F., Ffrench, M., Garoscio, M., Felman, P., Coiffier, B. Bryon, P.A. (1993) Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias. Blood, 81, 3063 3067.
71. Rosenberg, C.L., Wong, E., Petty, E.M., Bale, A.E., Tsujimoto, Y., Harris, N.L. Arnold, A. (1991) PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proceedings of the National Academy of Sciences of the USA, 88, 9638 9642.
72. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., Leblanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. Staudt, L.M. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346, 1937 1947.
73. Rosenwald, A., Wright, G., Wiestner, A., Chan, W.C., Connors, J.M., Campo, E., Gascoyne, R.D., Grogan, T.M., Muller-Hermelink, H.K., Smeland, E.B., Chiorazzi, M., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Henrickson, S., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Montserrat, E., Bosch, F., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Fisher, R.I., Miller, T.P., Leblanc, M., Ott, G., Kvaloy, S., Holte, H., Delabie, J. Staudt, L.M. (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3, 185 197.
74. Sapra, P., Moase, E.H., Ma, J. Allen, T.M. (2004) Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clinical Cancer Research, 10, 1100 1111.
75. Savage, K.J., Monti, S., Kutok, J.L., Cattoretti, G., Neuberg, D., de, L.L., Kurtin, P., Dal, C.P., Ladd, C., Feuerhake, F., Aguiar, R.C., Li, S., Salles, G., Berger, F., Jing, W., Pinkus, G.S., Habermann, T., la-Favera, R., Harris, N.L., Aster, J.C., Golub, T.R. Shipp, M.A. (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 102, 3871 3879.
76. Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K.J., Shenkier, T., Sutherland, J., Gascoyne, R.D. Connors, J.M. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, 1857 1861.
77. Shapiro, G.I. (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of Clinical Oncology, 24, 1770 1783.
78. Shipp, M.A. (1994) Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood, 83, 1165 1173.
79. Shipp, M.A., Ross, K.N., Tamayo, P., Weng, A.P., Kutok, J.L., Aguiar, R.C., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G.S., Ray, T.S., Koval, M.A., Last, K.W., Norton, A., Lister, T.A., Mesirov, J., Neuberg, D.S., Lander, E.S., Aster, J.C. Golub, T.R. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine, 8, 68 74.
80. Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., rranz-Saez, R., Au, W.Y., Bellei, M., Brice, P., Caballero, D., Coiffier, B., Conde-Garcia, E., Doyen, C., Federico, M., Fisher, R.I., Garcia-Conde, J.F., Guglielmi, C., Hagenbeek, A., Haioun, C., Leblanc, M., Lister, A.T., Lopez-Guillermo, A., McLaughlin, P., Milpied, N., Morel, P., Mounier, N., Proctor, S.J., Rohatiner, A., Smith, P., Soubeyran, P., Tilly, H., Vitolo, U., Zinzani, P.L., Zucca, E. Montserrat, E. (2004) Follicular lymphoma international prognostic index. Blood, 104, 1258 1265.
81. Strauss, S.J., Morschhauser, F., Rech, J., Repp, R., Solal-Celigny, P., Zinzani, P.L., Engert, A., Coiffier, B., Hoelzer, D.F., Wegener, W.A., Teoh, N.K., Goldenberg, D.M. Lister, T.A. (2006) Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 24, 3880 3886.
82. Tagawa, H., Suguro, M., Tsuzuki, S., Matsuo, K., Karnan, S., Ohshima, K., Okamoto, M., Morishima, Y., Nakamura, S. Seto, M. (2005) Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood, 106, 1770 1777.
83. Tiemann, M., Schrader, C., Klapper, W., Dreyling, M.H., Campo, E., Norton, A., Berger, F., Kluin, P., Ott, G., Pileri, S., Pedrinis, E., Feller, A.C., Merz, H., Janssen, D., Hansmann, M.L., Krieken, H., Moller, P., Stein, H., Unterhalt, M., Hiddemann, W. Parwaresch, R. (2005) Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. British Journal of Haematology, 131, 29 38.
84. Tilly, H., Rossi, A., Stamatoullas, A., Lenormand, B., Bigorgne, C., Kunlin, A., Monconduit, M. Bastard, C. (1994) Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood, 84, 1043 1049.
85. Tome, M.E., Johnson, D.B., Rimsza, L.M., Roberts, R.A., Grogan, T.M., Miller, T.P., Oberley, L.W. Briehl, M.M. (2005) A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. Blood, 106, 3594 3601.
86. Torlakovic, E.E., Bilalovic, N., Golouh, R., Zidar, A. Angel, S. (2006) Prognostic significance of PU.1 in follicular lymphoma. The Journal of Pathology, 209, 352 359.
87. Tsujimoto, Y., Yunis, J., Onorato-Showe, L., Erikson, J., Nowell, P.C. Croce, C.M. (1984) Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science, 224, 1403 1406.
88. Viardot, A., Moller, P., Hogel, J., Werner, K., Mechtersheimer, G., Ho, A.D., Ott, G., Barth, T.F., Siebert, R., Gesk, S., Schlegelberger, B., Dohner, H. Bentz, M. (2002) Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. Journal of Clinical Oncology, 20, 4523 4530.
89. Wiemik, P.H., Lossos, I., Tuscano, J., Justice, G., Vose, J.M., Pietronigro, D., Takeshita, K., Ervin-Haynes, A., Zeldis, J.B. Habermann, T.M. (2006) Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. Blood, 108, 160A 161A.
90. Wiestner, A., Tehrani, M., Chiorazzi, M., Wright, G., Gibellini, F., Nakayama, K., Liu, H., Rosenwald, A., Muller-Hermelink, H.K., Ott, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Vose, J., Armitage, J.O., Gascoyne, R.D., Connors, J.M., Campo, E., Montserrat, E., Bosch, F., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Fisher, R.I., Grogan, T.M., Miller, T.P., Wilson, W.H., Jaffe, E.S. Staudt, L.M. (2007) Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood, 109, 4599 4606.
91. Winter, J.N., Weller, E.A., Horning, S.J., Krajewska, M., Variakojis, D., Habermann, T.M., Fisher, R.I., Kurtin, P.J., Macon, W.R., Chhanabhai, M., Felgar, R.E., Hsi, E.D., Medeiros, L.J., Weick, J.K., Reed, J.C. Gascoyne, R.D. (2006) Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 107, 4207 4213.
92. Witzig, T.E., Geyer, S.M., Ghobrial, I., Inwards, D.J., Fonseca, R., Kurtin, P., Ansell, S.M., Luyun, R., Flynn, P.J., Morton, R.F., Dakhil, S.R., Gross, H. Kaufmann, S.H. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. Journal of Clinical Oncology, 23, 5347 5356.
93. Zinzani, P.L., Musuraca, G., Alinari, L., Fanti, S., Tani, M., Stefoni, V., Marchi, E., Fina, M., Pellegrini, C., Castellucci, P., Farsad, M. Baccarani, M. (2007) Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clinical Lymphoma & Myeloma, 7, 291 295.